Cohance Life
Cohance Life Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
H2 FY27 expected to show growth over the previous year with new molecules and reload/older molecules contributing (Umang Vohra). Growth in H2 FY27 is expected to be better than H1 due to new molecule additions and reload orders, particularly in Pharma CDMO and API+ segments.
From Cohance Life's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- H2 FY27 expected to show growth over the previous year with new molecules and reload/older molecules contributing (Umang Vohra).
- Pharma CDMO business projected to have strong sequential Q2FY27 growth compared to Q1FY27, with long-term growth driven by 7 product filings in FY27 (Gunjan Singh, Umang Vohra).
- API+ segment seen as a sustainable, growing business with potential to double over 3-4 years, driven by CNS focus and innovator relationships (Gunjan Singh).
- ADC business currently cost-heavy but expected to improve with pipeline development and revenue growth (Umang Vohra).
- Restocking impact (INR 260 crore) partially returning in FY27, with better clarity expected by second call (Himanshu Agarwal, Yann D’Herve).
- $1 billion sales target for FY30 is an aspiration; growth expected but not firmly quantified yet (Umang Vohra).
- Margin recovery and profitability expected to accelerate from FY28 onwards as operating leverage plays in (Himanshu Agarwal).
Profitability & Margins
See what Cohance Life said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure during the quarter was approximately INR 598 million, focused on investing in capabilities required for future growth.
- Investment includes a commercial flow reactor at the Jaggayyapet site, expected to be ready by next quarter.
- Completed debottlenecking initiatives for several products and commissioned a new effluent treatment facility at Ankleshwar to enhance capacity and compliance.
- Ongoing remediation and operational stabilization efforts at the Nacharam facility, supporting CAPA implementation and full normalization.
- The company is finalizing a dedicated R&D, manufacturing, and asset strategy for the Specialty Chemicals segment to support scale-up, safety, efficiency, and innovation.
- Investments target innovator-led programs and capacity expansion, particularly in Pharma CDMO, API+, and Specialty Chemicals to support future growth and market opportunities.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Cohance Life said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company experienced shipment timing and customer approval delays causing Q1FY27 revenue shortfall.
- A commercial restocking order has been secured, with deliveries scheduled across Q2FY27 and Q3FY27.
- The late-stage opportunity funnel has expanded, supporting growth momentum in the second half of FY27.
- The Pharma CDMO segment received meaningful delivery visibility for Q4 FY27 and FY28 due to restocking orders.
- RFQ pipeline is strengthening, backed by numerous Phase 3 KSM commercial supply inquiries from large pharma companies and Western CDMOs.
- Multiple customer programs have progressed through qualification stages, including two Japanese innovators' first qualifications scheduled in FY27.
- The company targets qualifying approximately two new products annually with existing and new European and Japanese customers.
- The commercial OTIF (On-Time In-Full) rate remains near 100%, indicating strong order fulfillment performance.
Cohance Life — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹619 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Cohance Lifesciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Cohance Life Q1 FY27 results?
H2 FY27 expected to show growth over the previous year with new molecules and reload/older molecules contributing (Umang Vohra). Growth in H2 FY27 is expected to be better than H1 due to new molecule additions and reload orders, particularly in Pharma CDMO and API+ segments.
What is Cohance Life share price analysis?
Cohance Life currently shows a below-average growth signal. The stock trades at a P/E of 164.5 with a market cap of ₹17,714 Cr. Investors should review the full earnings analysis for detailed insights.
Is Cohance Life planning capital expenditure?
Capital expenditure during the quarter was approximately INR 598 million, focused on investing in capabilities required for future growth.
Keep Cohance Life on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.